Comparison of one-week versus three-week paclitaxel for advanced pan-carcinomas: systematic review and meta-analysis
Figure 3.The forest plot of HR for PFS in the subgroup analysis based on carboplatin administration schedules. HR: hazard ratio; PFS: progression-free survival.